Publications - Joseph Lustgarten, Ph.D.

Back to Research Profile

1. Lustgarten J. Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 2009 Dec; 58(12):1979-89. Epub 2009 Feb 24.
   View PubMed
2. Sharma S, Dominguez AL, Manrique SZ, Cavallo F, Sakaguchi S, Lustgarten J. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res 2008 Sep 15; 68(18):7530-40.
   View PubMed
3. Sharma S, Dominguez AL, Zorro Manrique S, Cavallo F, Sakaguchi S, Lustgarten J. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res 2008 Sep 15; 68(18):7530-40.
   View PubMed
4. Dominguez AL, Lustgarten J. Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res 2008 Jul 1; 68(13):5423-31.
   View PubMed
5. Sharma S, Dominguez AL, Hoelzinger DB, Lustgarten J. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother 2008 Apr; 57(4):549-61. Epub 2007 Sep 08.
   View PubMed
6. Sharma S, Dominguez AL, Lustgarten J. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol 2006 Dec 15; 177(12):8348-55.
   View PubMed
7. Weidanz JA, Nguyen T, Woodburn T, Neethling FA, Chiriva-Internati M, Hildebrand WH, Lustgarten J. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol 2006 Oct 15; 177(8):5088-97.
   View PubMed
8. Lustgarten J, Dominguez AL, Pinilla C. Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope. J Immunol 2006 Feb 1; 176(3):1796-805.
   View PubMed
9. Sharma S, Dominguez AL, Lustgarten J. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Gerontol 2006 Jan; 41(1):78-84. Epub 2005 Nov 14.
   View PubMed
10. Weidanz JA, Woodburn D, Nguyen T, Neethling FA, Wittman VP, Lustgarten J. Levels of specific peptide-HLA Class I complex rather than TAA expression determines tumor cell susceptibility to CTL killing. J Immunol 2006; 177:5088.
    View PubMed
11. Linton PJ, Lustgarten J, Thoman ML. T cell function in the aged. Clinical and Applied Immunology Reviews 2006; 6:73.
12. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P, Lustgarten J. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer 2005 Oct 10; 116(6):934-43.
    View PubMed
13. Frost GI, Lustgarten J, Dudouet B, Nyberg L, Hartley-Asp B, Borgstrom P. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration. Microvasc Res 2005 Jan; 69(1-2):1-9.
    View PubMed
14. Frost G, Lustgarten J, Dudouet B, Nyberg L, Hartley-Asp B, Borgström P. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration. Microvasc Res 2005; 69:1-9.
    View PubMed
15. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgström P, Lustgarten J. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX-40 and anti-4-1BB monoclonal antibodies induce a T cell mediate protective immunity in Her-2/neu transgenic mice. Int J Cancer 2005; 116(6):934-43.
    View PubMed
16. Lustgarten J, Dominguez AL, Thoman M. Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 2004 Oct 1; 173(7):4510-5.
    View PubMed
17. Cuadros C, Lopez-Hernandez FJ, Dominguez AL, McClelland M, Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004 May; 72(5):2810-6.
    View PubMed
18. Lustgarten J, Dominguez AL, Cuadros C. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol 2004 Mar; 34(3):752-61.
    View PubMed
19. Dominguez AL, Caudros C, Lustgarten J. Dendritic cells pulsed with apoptotic tumors induce a protetive T cell immunity in tolerant Her-2/neu mice. International Proceedings, Immunology 2004:223-7.
    View PubMed
20. Lustgarten J. Anti-Her-2/neu-IL2 or heregluin-IL2 fusions proteins redirect non-tumor specific CTL to the tumorsite for tumor eradication. Cancer Immunol and Immunotherapy 2003; 52:751-60.
    View PubMed
21. Frost GI, Dudouet B, Lustgarten J, Borgström P. The roles of epithelial-mesynchymal interactions and the innate immune response on the tumorigenicity of human prostate carcinoma cell lines grown in immunocompromised mice. In Vivo 2003; 17:377-88.
    View PubMed
22. Caudros C, Dominguez AL, Frost G, Borgström P, Lustgarten J. Cooperative effect between immunotherapy and antiangiogenic therapy results in effective tumor rejection in tolerant Her-2/neu mice. Cancer Research 2003; 63:5895-901.
    View PubMed
23. Lustgarten J, Marks J, Sherman LA. Redirecting effector T cells through their IL-2 receptors. J Immunol 1999 Jan 1; 162(1):359-65.
    View PubMed
24. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA. Identification of Her-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Human Immunol 1997; 52:109-18.
    View PubMed
25. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185:833-41.
    View PubMed
26. Lustgarten J, Waks T, Eshhar Z. Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin. Mol Immunol 1996 Feb; 33(3):245-51.
    View PubMed
27. Eshhar Z, Gross G, Waks T, Lustgarten J, Bach N, Ratner A, Treisman J, Schindler D. T-bodies: chimeric T cell receptors with antibody-type specificity. Immunomethods 1995; 8:40-8.
    View PubMed
28. Lustgarten J, Eshhar Z. Specific elimination of IgE production using T cell lines expressing chimeric TCR genes. Eur J Immunol 1995; 29:2985-91.
    View PubMed
29. Gorochov G, Lustgarten J, Waks T, Gross G, Eshhar Z. Functional assembly of chimeric T cell receptor chains. International J of Cancer Suppl 1992(Suppl 7):53-7.
    View PubMed
30. Lustgarten J, Waks T, Eshhar Z. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex. Eur J Immunol 1991 Oct; 21(10):2507-15.
    View PubMed
31. Band H, Corredor V, Lustgarten J, Huebner K, Griffin JD, Kufe DW, Yunis EJ. Southern blot analysis of BII cell line--a putative variant of HL-60. Leukemia 1987 Feb; 1(2):142-5.
    View PubMed